Achieve Life Sciences, Inc.
ACHV · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $5,320 | $6,707 | $7,097 | $7,296 |
| G&A Expenses | $9,372 | $5,856 | $5,797 | $4,894 |
| SG&A Expenses | $9,372 | $5,856 | $5,797 | $4,894 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $14,692 | $12,563 | $12,894 | $12,190 |
| Operating Income | -$14,692 | -$12,563 | -$12,894 | -$12,190 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $251 | -$155 | $67 | -$170 |
| Pre-Tax Income | -$14,441 | -$12,718 | -$12,827 | -$12,360 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$14,441 | -$12,718 | -$12,827 | -$12,360 |
| % Margin | – | – | – | – |
| EPS | -0.28 | -0.37 | -0.37 | -0.36 |
| % Growth | 24.3% | 0% | -2.8% | – |
| EPS Diluted | -0.28 | -0.37 | -0.37 | -0.36 |
| Weighted Avg Shares Out | 34,685 | 34,685 | 34,685 | 34,511 |
| Weighted Avg Shares Out Dil | 34,685 | 34,685 | 34,685 | 34,511 |
| Supplemental Information | – | – | – | – |
| Interest Income | $554 | $192 | $322 | $482 |
| Interest Expense | $192 | $191 | $185 | $197 |
| Depreciation & Amortization | $55 | $55 | $62 | $58 |
| EBITDA | -$14,194 | -$12,472 | -$12,580 | -$12,105 |
| % Margin | – | – | – | – |